INTRODUCTION
Mul drug resistant (MDR) bacteria like Klebsiella pneumoniae and Staphylococcus aureus are common cause of pneumonia in most of intensive care unit. It is due to overuse, over the counter availability, lack of an bio c stewardship, prescrip on of an bio c by paramedics in 1 developing countries. There are different an bio c used in combina on to treat this infec on. There is no clinical trial and studies on combina on of Polymyxin B and Doxycline for treatment of MDR bacteria. This is first case report that has used Doxycycline in combina on with Polymyxin B for treatment of MDR bacteria pneumonia.
CASE HISTORY:

CASE 1
A 31 year male, with past history of depression under regular treatment presented with Cough, Fever, Shortness of breath, Vomi ng for three days. At presenta on his Glasgow Coma Scale (GCS) was 15/15, Pulse rate was 160 beats/per min, Blood pressure was 76/40 mm of Hg, Respiratory rate was 31 breaths/min with use of accessory muscles, Oxygen satura on was 78% on 15 litre oxygen and Temperature was 102°F. On ausculta on of chest, bilateral crepita on and wheeze was present. Cardiovascular examina on showed tachycardia. Other system examina ons were normal. Immediately pa ent was resuscitated and intubated.
His inves ga on profiles were as follows Total Leucocyte 3 3 count(TLC)-13500/mm , Platelets-90000/mm , Hemoglobin (Hb)-9gm/dl, Urea-90 mg/dl, Crea nine 1.4 mg/dl, Sodium and Potassium were normal. Total bilirubin 3.4mg/dl in which direct was 3mg/dl, Total protein 5.9mg/dl in which albumin was 3.1mg/dl, Alanine aminotransferase (ALT) 601U/L, Aspartate aminotransferase (AST) 681U/L. Chest x-ray showed bilateral pneumonia ( Figure 1 ). Pa ent was diagnosed as bilateral community acquired pneumonia with mul organ dysfunc on and sep c shock with acute kidney injury.
Klebsiella pneumoniae sensi ve to Polymyxin B, Chloramphenicol and Doxycycline. Pa ent was started on Polymyxin B 10 lac two mes a day and doxycycline 200 milligram two mes a day. Pa ent got extubated on fi h day and was transferred out on seventh day and an bio c was th con nued for 14 days. Pa ent was discharged on 15 day.
CASE 2
A 38 year old chronic alcoholic male, presented with complain of severe abdominal pain, nausea vomi ng for a dura on of two days. At presenta on, his Glasgow Coma Scale (GCS) was 15/15, Pulse rate was 138 beats/per min, Blood pressure was 110/800 mmHg, Respiratory rate was 26 breaths/min, Oxygen satura on was 94% on 5 liter oxygen, and Temperature was 98°F. On examina on there was tenderness at epigastric region. Other systems examina ons 3 were normal. His inves ga on profile was TLC-17000/mm , 3 Platelets-110000/mm , Hb-10gm/dl, Urea-90 mg/dl, Crea nine-1.9 mg/dl, Sodium and Potassium were normal. Total bilirubin 6mg/dl in which direct 2.3mg/dl, total protein 5.9mg/dl in which albumin 2.9 mg/dl, ALT-1021U/L, AST-1821U/L. Serum amylase 1017 U/L, Lipase 2012 U/L. He was diagnosed to have acute severe alcoholic pancrea s. He was managed conserva vely with fluids and analgesics. On 6th day he developed fever and shortness of breath. Chest xray showed bilateral pneumonia (Figure 2 ). Sputum and blood culture showed Vancomycin resistant Staphylococcus aureus sensi ve to Polymyxin B and Doxycycline. He was started on Polymyxin B 10 lac two mes a day and Doxycycline 200 milligram two mes a day. He was treated for 14 days.
Pa ent was started empirically on Meropenem, Levofloxacin, and other suppor ve treatment with Vasopressors, Hydrocor sone, Fluids and Ven lator support. On third day there was no improvement and sputum culture report showed Carbapenem resistant 
DISCUSSION
Studies have shown that prevalence of mul drug resistant [1] [2] [3] bacteria in intensive care unit ranges from 20 to 96%. Gram nega ve infec ons are most MDR followed by gram posi ve in developing and developed country respec vely in 2 Intensive Care Unit(ICU). An bio c resistance and MDR pathogens is a serious problem all over the globe but is more common in south east Asia and middle east due to over the counter availability of an bio c. There are no studies on combina on of Polymyxin B and Doxycycline for treatment of MDR bacteria so, large scale studies are required to show the efficacy of this combina on.
CONCLUSION
New an bio c has not been developed in pace with growth of MDR organisms. Therefore, treatment with older an bio c like Polymyxin B and Doxycycline in combina on may play a role in treatment of MDR bacteria induced pneumonia and bacteremia but requires large scale randomized control trial to show the benefit of combina on therapy.
